These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29487712)

  • 1. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
    Zhang Q; Shi C; Han L; Jain N; Roberts KG; Ma H; Cai T; Cavazos A; Tabe Y; Jacamo RO; Mu H; Zhao Y; Wang J; Wu SC; Cao F; Zeng Z; Zhou J; Mi Y; Jabbour EJ; Levine R; Tasian SK; Mullighan CG; Weinstock DM; Fruman DA; Konopleva M
    Oncotarget; 2018 Jan; 9(8):8027-8041. PubMed ID: 29487712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
    Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
    Tasian SK; Doral MY; Borowitz MJ; Wood BL; Chen IM; Harvey RC; Gastier-Foster JM; Willman CL; Hunger SP; Mullighan CG; Loh ML
    Blood; 2012 Jul; 120(4):833-42. PubMed ID: 22685175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
    Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
    Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
    Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
    Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
    Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
    PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
    Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
    Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
    Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
    Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
    Ding YY; Kim H; Madden K; Loftus JP; Chen GM; Allen DH; Zhang R; Xu J; Chen CH; Hu Y; Tasian SK; Tan K
    Clin Cancer Res; 2021 Sep; 27(18):5109-5122. PubMed ID: 34210682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
    Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
    Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
    Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
    Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
    Savino AM; Sarno J; Trentin L; Vieri M; Fazio G; Bardini M; Bugarin C; Fossati G; Davis KL; Gaipa G; Izraeli S; Meyer LH; Nolan GP; Biondi A; Te Kronnie G; Palmi C; Cazzaniga G
    Leukemia; 2017 Nov; 31(11):2365-2375. PubMed ID: 28331226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.
    Hurtz C; Wertheim GB; Loftus JP; Blumenthal D; Lehman A; Li Y; Bagashev A; Manning B; Cummins KD; Burkhardt JK; Perl AE; Carroll M; Tasian SK
    J Clin Invest; 2020 Jul; 130(7):3637-3653. PubMed ID: 32191635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
    Jain N; Roberts KG; Jabbour E; Patel K; Eterovic AK; Chen K; Zweidler-McKay P; Lu X; Fawcett G; Wang SA; Konoplev S; Harvey RC; Chen IM; Payne-Turner D; Valentine M; Thomas D; Garcia-Manero G; Ravandi F; Cortes J; Kornblau S; O'Brien S; Pierce S; Jorgensen J; Shaw KR; Willman CL; Mullighan CG; Kantarjian H; Konopleva M
    Blood; 2017 Feb; 129(5):572-581. PubMed ID: 27919910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia.
    Daenthanasanmak A; Lin Y; Zhang M; Bryant BR; Petrus MN; Bamford RN; Thomas CJ; Miljkovic MD; Conlon KC; Waldmann TA
    Transl Oncol; 2021 Jan; 14(1):100913. PubMed ID: 33129109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia.
    Alkashgari HR; Ruiz-Jimenez C; Stoian C; Coats JS; Baez I; Chirshev E; Martinez SR; Dovat S; Francis-Boyle OL; Casiano CA; Payne KJ
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph
    Vo TT; Lee JS; Nguyen D; Lui B; Pandori W; Khaw A; Mallya S; Lu M; Müschen M; Konopleva M; Fruman DA
    Mol Cancer Ther; 2017 Sep; 16(9):1942-1953. PubMed ID: 28566433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.
    Roberts KG; Yang YL; Payne-Turner D; Lin W; Files JK; Dickerson K; Gu Z; Taunton J; Janke LJ; Chen T; Loh ML; Hunger SP; Mullighan CG
    Blood Adv; 2017 Sep; 1(20):1657-1671. PubMed ID: 29296813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.